Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

The invention relates to the preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid. The invention also relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid in pharmaceutical compositions in drug delivery systems for humans. The invention further relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid or the pharmaceutical compositions thereof to treat and/or prevent a disease state associated with osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, Paget's disease or for adjuvant or neoadjuvant therapies.

The invention relates to the preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid. The invention also relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid in pharmaceutical compositions in drug delivery systems for humans. The invention further relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid or the pharmaceutical compositions thereof to treat and/or prevent a disease state associated with osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, Paget's disease or for adjuvant or neoadjuvant therapies.

Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

According to a nonaqueous electrolytic solution containing: a compound represented by General Formula (1); a solute; and a nonaqueous organic solvent, a nonaqueous electrolytic solution battery, and a compound represented by the General Formula (1), a nonaqueous electrolytic solution and a nonaqueous electrolytic solution battery having a low initial resistance value, and a compound that can be suitably used for the above nonaqueous electrolytic solution are provided.

##STR00001##

According to a nonaqueous electrolytic solution containing: a compound represented by General Formula (1); a solute; and a nonaqueous organic solvent, a nonaqueous electrolytic solution battery, and a compound represented by the General Formula (1), a nonaqueous electrolytic solution and a nonaqueous electrolytic solution battery having a low initial resistance value, and a compound that can be suitably used for the above nonaqueous electrolytic solution are provided.

##STR00001##